Fusion Pharmaceuticals’ Partnerships Strengthen Long-Term Outlook (NASDAQ:FUSN)

Dr_Microbe Fusion Pharmaceuticals (NASDAQ:FUSN) emerges as an interesting story in the oncology sector, especially in the niche but growing radiopharmaceuticals segment. The appeal of Fusion lies in its approach to precision oncology, particularly with its clinical candidates’ portfolio for a range of cancers. The company’s investment attractiveness is anchored by its commitment to innovation, including…

Read More

Voyager Therapeutics’ Strategic Partnerships And TRACER Technology – Speculative Buy

yacobchuk Voyager Therapeutics, Inc. (NASDAQ:VYGR) is a promising biotechnology firm in gene therapy treatments for central nervous system [CNS] diseases. The company’s product pipeline remains in preclinical trials for therapies against Parkinson’s disease, amyotrophic lateral sclerosis [ALS], and Alzheimer’s disease. The journey to complete the clinical trials for these therapies is extensive. However, VYGR’s most…

Read More

Algorand Expands Its Presence in India with Key Partnerships

Algorand entered the Indian market earlier this year with the launch of the AlgoBharat Project. One of the first collaborations was formed with the Self-Employed Women’s Association (SEWA).  Blockchain protocol Algorand (ALGO) has announced its expansion into India through major collaborations with prominent organizations including NASSCOM, TiE Bangalore, and the Mann Deshi Foundation. Algorand’s Impact…

Read More

N-able Q3: Robust Partnerships, Rising Demand, Strengthened Finances (NYSE:NABL)

LeoWolfert/iStock via Getty Images I assessed N-able, Inc. (NYSE:NABL) a year ago and suggested a hold rating, considering its declining stock trend post-spinoff from SolarWinds Corporation. Despite robust financial performance, uncertainties in the IT industry and limited financial history prompted a cautious approach. However, its recent Q3 2023 report reveals a 15% YoY revenue surge…

Read More